SEARCH

SEARCH BY CITATION

References

  • Åberg F, Rissanen AM, Sintonen H, Roine RP, Höckerstedt K, Isoniemi H. 2009. Health-related quality of life and employment status of liver transplant patients. Liver Transplant 15(1):6472.
  • Adachi M, Brenner DA. 2005. Clinical syndromes of alcoholic liver disease. Dig Dis 23(3–4):25563.
  • Adams BK, Cai J, Armstrong J, Herold M, Lu YJ, Sun A, Snyder JP, Liotta DC, Jones DP, Shoji M. 2005. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anti-cancer Drug 16(3):26375.
  • Adams J. 2004. The proteasome: a suitable antineoplastic target. Nature Rev Can 4(5):34960.
  • Adhvaryu MR, Reddy N, Parabia MH. 2007. Effects of four Indian medicinal herbs on isoniazid-z, rifampicin and pyrazinamide-induced hepatic injury and immunosuppression in guinea pigs. World J Gastroenterol 13(23):3199205.
  • Agrawal DK, Mishra PK. 2009. Curcumin and its analogues: potential anticancer agents. Med Res Rev 30(5):81860.
  • Aggarwal BB, Kumar A, Bharti AC. 2003. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23(1A):36398.
  • Aggarwal BB, Sung B. 2009. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trend Pharmacol Sci 30(2):8594.
  • Ahmed T, Pathak R, Mustafa MD, Kar R, Tripathi AK, Ahmed RS, Banerjee BD. 2011. Ameliorating effect of N-acetylcysteine and curcumin on pesticide-induced oxidative DNA damage in human peripheral blood mononuclear cells. Environ Monit Assess 179(1):2939.
  • Alavian SM, Ahmadzad-Asl M, Lankarani KB, Shahbabaie MA, Ahmadi AB, Kabir A. 2009. Hepatitis C infection in the general population of Iran: a systematic review. Hepat Mon 9(3):21123.
  • Aljiffry M, Renfrew PD, Walsh MJ, Laryea M, Molinari M. 2011. Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis. HPB 13(2):7990.
  • Alsohaibani F, Porter G, Al-Ashgar H, Walsh M, Berry R, Molinari M, Peltekian KM. 2011. Comparison of cancer care for hepatocellular carcinoma at two tertiary-care referral centers from high and low endemic regions for viral hepatitis. J Gastrointest Cancer 42(4):22835.
  • Amorati R, Menichetti S, Mileo E, Pedulli GF, Viglianisi C. 2009. Hydrogen-atom transfer reactions from ortho-alkoxy-substituted phenols: an experimental approach. Chemistry Eur J 15(17):440210.
  • Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, Tharakan ST, Misra K, Priyadarsini IK, Rajasekharan KN, Aggarwal BB. 2008. Biological activities of curcumin and its analogues (congeners) made by man and mother nature. Biochem Pharmacol 76(11):1590611.
  • Angelo LS, Kurzrock R. 2009. Turmeric and green tea: a recipe for the treatment of B-chronic lymphocytic leukemia. Clin Cancer Res 15(4):11235.
  • Angulo P. 2002. Nonalcoholic fatty liver disease. N Engl J Med 346(16):122131.
  • Arun N, Nalini N. 2002. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Food Human Nutr 57(1):4152.
  • Augello C, Caruso L, Maggioni M, Donadon M, Montorsi M, Santambrogio R, Torzilli G, Vaira V, Pellegrini C, Roncalli M, Coggi G, Bosari S. 2009. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 9(1):125.
  • Aung W, Hasegawa S, Furukawa T, Saga T. 2007. Potential role of ferritin heavy chain in oxidative stress and apoptosis in human mesothelial and mesothelioma cells: implications for asbestos-induced oncogenesis. Carcinogenesis 28(9):204752.
  • Azizi L, Raynal M, Cazejust J, Ruiz A, Menu Y, Arrivé L. 2012. MR imaging of sclerosing cholangitis. Clinics Res Hepatol Gastroenterol 36(2):1308.
  • Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thüringer A, Leski K, Fickert P, Karpen SJ, Trauner M. 2010. Curcumin improves sclerosing cholangitis in Mdr2−/− mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 59(4):52130.
  • Bakhshi J, Weinstein L, Poksay KS, Nishinaga B, Bredesen DE, Rao RV. 2008. Coupling endoplasmic reticulum stress to the cell death program in mouse melanoma cells: effect of curcumin. Apoptosis 13(7):90414.
  • Baldi A, Lombardi D, Russo P, Palescandolo E, De Luca A, Santini D, Baldi F, Rossiello L, Dell'Anna ML, Mastrofrancesco A, Maresca V, Flori E, Natali PG, Picardo M, Paggi MG. 2005. Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. Clin Cancer Res 11(9):317583.
  • Balsano C, Alisi A. 2008. Viral hepatitis B: established and emerging therapies. Curr Med Chem 15(9):9309.
  • Bae MK, Kim SH, Jeong JW, Lee YM, Kim HS, Kim SR, Yun I, Bae SK, Kim KW. 2006. Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncology Rep 15(6):155762.
  • Bao W, Li K, Rong S, Yao P, Hao L, Ying C, Zhang X, Nussler A, Liu L. 2010. Curcumin alleviates the ethanol-induced hepatocytes oxidative damageinvolving heme oxygenase-1 induction. J Ethnopharmacol 128:54953.
  • Bar-Sela G, Epelbaum R, Schaffer M. 2010. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 17(3):1907.
  • Basnet P, Skalko-Basnet N. 2011. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 16(6):456798.
  • Bataller R, Rombouts K, Altamirano J, Marra F. 2011. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 25(2):23144.
  • Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V. 2008. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28(1):1103.
  • Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Crocè LS, Sasso F, Pozzato G, Cristianini G, Brandi G. 1997. Drinking habits as cofactors of risk for alcohol-induced liver damage. Gut 41(6):84550.
  • Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, Christianini G. 2005. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 20(6):14429.
  • Benvegnù L, Fattovich G, Noventa F, Tremolada F, Chemello L, Cecchetto A, Alberti A. 2006. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 74(9):24428.
  • Benzie IFF, Wachtel-Galor S. 2011. Herbal medicine: biomolecular and clinical aspects. 2nd ed. Boca Raton, FL: CRC Press.
  • Binion DG, Otterson MF, Rafiee P. 2008. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 57(11):150917.
  • Bishayee A, Darvesh AS, Politis T, McGory R. 2010. Resveratrol and liver disease: from bench to bedside and community. Liver Intl 30(8):110314.
  • Bowlus CL. 2011. Primary sclerosing cholangitis. In: Lawrence S. Friedman, Emmet B. Keeffe, editor. Handbook of liver disease. Philadelphia, PA: Elsevier. p 208.
  • Branton MH, Kopp JB. 1999. TGF-β and fibrosis. Microbes Infect 1(15):134965.
  • Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. 2005. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis. A case–control Study. Arterioscler Thromb Vasc Biol 25(5):104550.
  • Brunt EM. 2010. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7(4):195203.
  • Brunt EM. 2012. Histological assessment of nonalcoholic fatty liver disease in adults and children. Clin Liver Dis 1(4):10710.
  • Bubici C, Papa S, Dean K, Franzoso G. 2006. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 25(51):673148.
  • Bulku E, Stohs JS, Cicero L, Brooks T, Halley H, Ray SD. 2012. Curcumin exposure modulates multiple pro-apoptotic and anti-apoptotic signaling pathways to antagonize acetaminophen-induced toxicity. Curr Neurovasc Res 9(1):5871.
  • Burgos-Morón E, Calderón-Montaño JM, Salvador J, Robles A, López-Lázaro M. 2010.The dark side of curcumin. Intl J Cancer 126(7):17715.
  • Calin GA, Croce CM. 2006. MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):85766.
  • Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M, Sperlongano P, Vincenzi B, Naviglio S, Prete SD, Abbruzzese A, Stiuso P. 2011. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis 2(4):e150.
  • Chai H, Yan S, Lin P, Lumsden AB, Yao Q, Chen C. 2005. Curcumin blocks HIV protease inhibitor ritonavir-induced vascular dysfunction in porcine coronary arteries. J Am Coll Surg 200(6):82030.
  • Chan MMY. 1995. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 49(11):15516.
  • Chan WH, Wu CC, Yu JS. 2003. Curcumin inhibits UV irradiation-induced oxidative stress and apoptotic biochemical changes in human epidermoid carcinoma A431 cells. J Cell Biochem 90(2):32738.
  • Chang TC, Mendell JT. 2007. MicroRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet 8:21539.
  • Chang YC, Xu YH. 2000. Expression of Bcl-2 inhibited Fas-mediated apoptosis in human hepatocellular carcinoma BEL-7404 cells. Cell Res 10(3):23342.
  • Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. 2010. Diagnosis and management of primary sclerosing cholangitis. Hepatology 51(2):66078.
  • Chaturvedi TP. 2009. Uses of turmeric in dentistry: an update. Ind J Dent Res 20(1):1079.
  • Chekulaeva M, Filipowicz W. 2009. Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol 21(3):45260.
  • Chen A, Zheng S. 2008. Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF-κB and ERK signalling. Br J Pharmacol 153(3):55767.
  • Chen HW, Huang HC. 2009. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br J Pharmacol 124(6):102940.
  • Chen MH, Lee MY, Chuang JJ, Li YZ, Ning ST, Chen JC, Liu YW. 2012. Curcumin inhibits HCV replication by induction of heme oxygenase-1 and suppression of AKT. Intl J Mol Med 30(5):10218.
  • Chen DY, Shien JH, Tiley L, Chiou SS, Wang SY, Chang TJ, Lee YJ, Chan KW, Hsu WL. 2010. Curcumin inhibits influenza virus infection and haemagglutination activity. Food Chem 119(4):134651.
  • Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. 2011. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA 306(17):188490.
  • Cheng CY, Lin YH, Su CC. 2010. Curcumin inhibits the proliferation of human hepatocellular carcinoma J5 cells by inducing endoplasmic reticulum stress and mitochondrial dysfunction. Intl J Mol Med 26(5):6738.
  • Chuan-Xing L, Xu H, Bao-Shan H, Yong L, Pei-Jian S, Xian-Yi Y, Xiao-Ning L, Li-Gong L. 2011. Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed. Cancer Biol Ther 12(10):86571.
  • Chun KS, Keum YS, Han SS, Song YS, Kim SH, Surh YJ. 2003. Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-κB activation. Carcinogenesis 24(9):151524.
  • Clark JM, Diehl AM. 2003. Nonalcoholic fatty liver disease. JAMA 289(22):30004.
  • Conteas CN, Panossian AM, Tran TT, Singh HM. 2009. Treatment of HIV-associated diarrhea with curcumin. Dig Dis Sci 54(10):218891.
  • Croce CM, Calin GA. 2005. miRNAs, cancer, and stem cell division. Cell 122(1):67.
  • Cullen S, Chapman R. 2003. Primary sclerosing cholangitis. Autoimmun Rev 2(6):30512.
  • Dance-Barnes ST, Kock ND, Moore JE, Lin EY, Mosley LJ, D'Agostino Jr RB, McCoy TP, Townsend AJ, Miller MS 2009. Lung tumor promotion by curcumin. Carcinogenesis 30(6):101623.
  • Danielsson Ä, Boqvist L, Uddenfeldt P. 2005. Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. Hepatology 11(3):45864.
  • Darvesh AS, Aggarwal BB, Bishayee A. 2012. Curcumin and liver cancer: a review. Curr Pharm Biotechnol 13(1):21828.
  • Das T, Sa G, Saha B, Das K. 2010. Multifocal signal modulation therapy of cancer: ancient weapon, modern targets. Mol Cell Biochem 336(1):8595.
  • Dattani JJ, Rajput DK, Moid N, Highland HN, George LB, Desai KR. 2010. Ameliorative effect of curcumin on hepatotoxicity induced by chloroquine phosphate. Environ Toxicol Pharmacol 30(2):1039.
  • De Francesco R. 1999. Molecular virology of the hepatitis C virus. J Hepatol 31:4753.
  • Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M, Chevret S. 2000. Hepatitis C virus-related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 47(1):1316.
  • Delhalle S, Deregowski V, Benoit V, Merville MP, Bours V. 2002. NF-kappaB-dependent MnSOD expression protects adenocarcinoma cells from TNF-alpha-induced apoptosis. Oncogene 21(24):391724.
  • Deng S, Calin GA, Croce CM, Coukos G, Zhang L. 2008. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 7(17):26436.
  • Deveraux QL, Reed JC. 1999. IAP family proteins-suppressors of apoptosis. Genes Dev 13(3):23952.
  • Dienes HP, Lohse AW, Gerken G, Schirmacher P, Gallati H, Löhr HF, zum Büschenfelde KM. 1997. Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis. Virchows Arch 431(2):11924.
  • Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. 2004. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 10(6):8948.
  • Duclos-Vall JC, Capel F, Mabit H, Petit MA. 1998. Phosphorylation of the hepatitis B virus core protein by glyceraldehyde-3-phosphate dehydrogenase protein kinase activity. J Gen Virol 79(7):166570.
  • Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E. 2005. Chemopreventive and therapeutic effects of curcumin. Cancer Lett 223(2):18190.
  • EFSA Panel on Food Additives and Nutrient Sources Added to Food (ANS). 2010. Scientific opinion on the re-evaluation of curcumin (E 100) as a food additive. EFSA J 8(9):146. Doi: 10.2903/j.efsa.2010.1679.
  • Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glöckner-Pagel J, Canny S, Du K, Lukacs GL, Caplan MJ. 2004. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304(5670):6002.
  • Elfaki DAH, Lindor KD. 2011. Antibiotics for the treatment of primary sclerosing cholangitis. Am J Ther 18(3):2615.
  • El-Serag HB. 2004. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127(5):S27S34.
  • Fabbrini E, Sullivan S, Klein S.2009. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51(2):67989.
  • Farinati F, Cardin R, Bortolami M, Burra P, Russo FP, Rugge M, Guido M, Sergio A, Naccarato R. 2007. Hepatitis C virus: from oxygen-free radicals to hepatocellular carcinoma. J Viral Hepat 14(12):8219.
  • Feng JY, Liu ZQ. 2009. Phenolic and enolic hydroxyl groups in curcumin: which plays the major role in scavenging radicals? J Agric Food Chem 57(22):110416.
  • Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Intl J Cancer 127(12):2893917.
  • Fung J, Lai CL, Seto WK, Yuen MF. 2011. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 66(12):271525.
  • Gaedeke J, Noble NA, Border WA. 2004. Curcumin blocks multiple sites of the TGF-β signaling cascade in renal cells. Kidney Intl 66(1):11220.
  • Ganem D, Prince AM. 2004. Hepatitis B virus infection – natural history and clinical consequences. N Engl J Med 350(11):111829.
  • Ganiger S, Malleshappa HN, Krishnappa H, Rajashekhar G, Ramakrishna Rao V, Sullivan F. 2007. A two generation reproductive toxicity study with curcumin, turmeric yellow, in wistar rats. Food Chem Toxicol 45(1):649.
  • Gao M, Liu L, Zhang P, Yu G, Li Y. 2012. Neuroprotective effect of curcumin involved in increasing the protein levels of UCP2 and inhibiting oxidative stress induced by chronic cerebral ischemia in vitro. Mol Neurodegener 7:S26.
  • Garzon R, Calin GA, Croce CM. 2009. MicroRNAs in cancer. Annu Rev Med 60:16779.
  • Glebe D. 2007. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroentrol 13(1):1421.
  • Goel A, Kunnumakkara AB, Aggarwal BB. 2008. Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol 75(4):787809.
  • Grattagliano I, Bonfrate L, Diogo CV, Wang HH, Wang DQ, Portincasa P. 2009. Biochemical mechanisms in drug-induced liver injury: certainties and doubts. World J Gastroenterol 15(39):486576.
  • Girish C, Koner BC, Jayanthi S, Rao KR, Rajesh B, Pradhan SC. 2009. Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol-induced liver toxicity in mice. Fundam Clin Pharmacol l23(6):73545.
  • Gunawan BK, Kaplowitz N. 2007. Mechanisms of drug-induced liver disease. Clin Liver Dis 11(3):45975.
  • Gunaydın M, Guzel A, Guzel A, Alacam H, Salis O, Murat N, Gacar A, Guvenc T. 2012. The effect of curcumin on lung injuries in a rat model induced by aspirating gastrointestinal decontamination agents. J Pediatr Surg 47(9):166976.
  • Guo H, Ingolia NT, Weissman JS, Bartel DP. 2010. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466(7308):83540.
  • Gupta SC, Kismali G, Aggarwal BB. 2013. Curcumin, a component of turmeric: from farm to pharmacy. BioFactors 39:213.
  • Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. 2008. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65(11):163152.
  • Harrison RF, Davies MH, Neuberger JM, Hubscher SG. 2005. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis? Hepatology 20(2):35661.
  • Hart CL, Morrison DS, Batty GD, Mitchell RJ, Smith GD. 2010. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. Br Med J 340:C1420.
  • Hassan ZK, Al-Olayan EM. 2012. Curcumin reorganizes miRNA expression in a mouse model of liver fibrosis. Asia Pac J Cancer Prev 13(11):54058.
  • Hayakawa H, Minaniya Y, Ito K, Yamamoto Y, Fukuda T. 2011. Difference of curcumin content in curcuma longa L.(Zingiberaceae) caused by hybridization with other Curcuma species. Am J Plant Sci 2(2):1119.
  • He L, Hannon GJ. 2004. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Gen 5(7):52231.
  • Hemeida RA, Mohafez OM. 2008. Curcumin attenuates methotraxate-induced hepatic oxidative damage in rats. J Egypt Natl Cancer Inst 20(2):1418.
  • Holt PR, Katz S, Kirshoff R. 2005. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 50(11):21913.
  • Hong J, Bose M, Ju J, Ryu JH, Chen X, Sang S, Lee MJ, Yang CS. 2004. Modulation of arachidonic acid metabolism by curcumin and related β-diketone derivatives: effects on cytosolic phospholipase A2, cyclooxygenases and 5-lipoxygenase. Carcinogenesis 25(9):16719.
  • Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, Tian W, Zhang Q, Wang C, Zhang Q, Zhuang SM, Zheng L, Liang A, Tao W, Cao X. 2011. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19(2):23243.
  • Hu KQ. 2008. Hepatitis B virus (HBV) infection in Asian and Pacific Islander Americans (APIAs): how can we do better for this special population & quest. Am J Gastroenterol 103(7):182433.
    Direct Link:
  • Huang MT, Wang ZY, Georgiadis CA, Laskin JD, Conney AH. 1992. Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene. Carcinogenesis 13(11):21836.
  • Ibrahim SH, Lindor KD. 2011. Current management of primary sclerosing cholangitis in pediatric patients. Pediatr Drugs 13(2):8795.
  • Invernizzi P, Miozzo M, Battezzati PM, Bianchi I, Grati FR, Simoni G, Selmi C, Watnik M, Gershwin ME, Podda M. 2004. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 363(9408):5335.
  • Iorio MV, Croce CM. 2009. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27(34):584856.
  • Itokawa H, Shi Q, Akiyama T, Morris-Natschke SL, Lee KH. 2008. Recent advances in the investigation of curcuminoids. Chin Med 3:11.
  • Jazayeri SM, Alavian SM, Carman WF.2009. Hepatitis B virus: origin and evolution. J Viral Hepat 17(4):22935.
  • Jemal A, Simard EP, Xu J, Ma J, Anderson RN. 2012. Selected cancers with increasing mortality rates by educational attainment in 26 states in the United States, 1993–2007. Cancer Causes Control 2012:17.
  • Jeong SO, Oh GS, Ha HY, Soon Koo B, Kim HS, Kim YC, Kim EC, Lee KM, Chung HT, Pae HO. 2009. Dimethoxycurcumin, a synthetic curcumin analogue, induces heme oxygenase-1 expression through Nrf2 activation in RAW264. 7 macrophages. J Clin Biochem Nutr 44:7984.
  • Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. 2009. Clinical course of alcoholic liver cirrhosis: a danish population-based cohort study. Hepatology 51(5):167582.
  • Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW. 2009. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361(15):143747.
  • John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. 2004. Human microRNA targets. PLoS Biol 2(11):e363.
  • Johnson JJ, Mukhtar H. 2007. Curcumin for chemoprevention of colon cancer. Cancer Lett 255(2):17081.
  • Jørgensen KK, Grzyb K, Lundin KE, Clausen OP, Aamodt G, Schrumpf E, Vatn MH, Boberg KM. 2012. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 18(3):53645.
  • Kakran M, Sahoo NG, Tan IL, Li L. 2012. Preparation of nanoparticles of poorly water-soluble antioxidant curcumin by antisolvent precipitation methods. J Nanoparticle Res 14(3):111.
  • Kamisawa T, Takuma K, Anjiki H, Egawa N, Kurata M, Honda G, Tsuruta K. 2009. Sclerosing cholangitis associated with autoimmune pancreatitis differs from primary sclerosing cholangitis. World J Gastroenterol 15(19):235760.
  • Kaplan MM, Gershwin ME. 2005. Primary biliary cirrhosis. N Engl J Med 353(12):126173.
  • Kang Q, Chen A. 2009. Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells. Br J Pharmacol 157(8):135467.
  • Kaplowitz N. 2004. Drug-induced liver injury. Clin Infect Dis 38:S448.
  • Kaplowitz N. 2005. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Dis 4(6):48999.
  • Kasof GM, Gomes BC. 2001. Livin, a novel inhibitor of apoptosis protein family member. Sci Signal 276(5):323846.
  • Khanna D, Sethi G, Ahn KS, Pandey MK, Kunnumakkara AB, Sung B, Aggarwal A, Aggarwal BB. 2007. Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol 7(3):34451.
  • Kim Im H, Huang H, Cheepala S, Huang S, Chung J. 2008. Curcumin inhibition of integrin (α6β4)-dependent breast cancer cell motility and invasion. Cancer Prev Res 1(5):38591.
  • Kim K, Kim KH, Kim HY, Cho HK, Sakamoto N, Cheong J. 2010. Curcumin inhibits hepatitis C virus replication via suppressing the Akt-SREBP-1 pathway. FEBS Lett 584(4):70712.
  • Kim SG, Veena MS, Basak SK, Han E, Tajima T, Gjertson DW, Starr J, Eidelman O, Pollard HB, Srivastava M, Srivatsan ES, Wang MB. 2011. Curcumin treatment suppresses IKKβ kinase activity of salivary cells of patients with head and neck cancer: a pilot study. Clin Cancer Res 17:595361.
  • Kim CH, Younossi ZM. 2008. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleveland Clin J Med 75(10):7218.
  • Kowluru RA, Kanwar M. 2007. Effects of curcumin on retinal oxidative stress and inflammation in diabetes. Nutr Metab (Lond) 4:8.
  • Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. 2002. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 89(4):41822.
  • Kuhad A, Chopra K. 2007. Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. Eur J Pharmacol 576(1):3442.
  • Kunnumakkara AB, Anand P, Aggarwal BB. 2008. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269(2):199225.
  • Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. 2007. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB–regulated gene products. Cancer Res 67(8):385361.
  • Kurd SK, Smith N, VanVoorhees A, Troxel AB, Badmaev V, Seykora JT, Gelfand JM. 2008. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. J Am Acad Dermatol 58(4):62531.
  • Kutluay SB, Doroghazi J, Roemer ME, Triezenberg SJ. 2008. Curcumin inhibits Herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity. Virology 373(2):23947.
  • Kwon YW, Kwon KS, Moon HE, Park JA, Choi KS, Kim YS, Jang HS, Oh CK, Lee YM, Kwon YG, Lee YS, Kim KW. 2003. Insulin-like growth factor-II regulates the expression of vascular endothelial growth factor by the human keratinocyte cell line HaCaT. J Invest Dermatol 123(1):1528.
  • Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. 2008. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47(6):195563.
  • Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS. 2008. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology 135(4):132232.
  • Lavanchy D. 2005. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 34:S1S3.
  • Leask A, Abraham DJ. 2004. TGF-β signaling and the fibrotic response. FASEB J 18(7):81627.
  • Leclercq IA, Farrell GC, Sempoux C, Horsmans Y. 2004. Curcumin inhibits NF-κB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 41(6):92634.
  • Lee WM. 2003. Drug-induced hepatotoxicity. N Engl J Med 349(5):47485.
  • Lee YM, Kaplan MM. 2002. Management of primary sclerosing cholangitis. Am J Gastroenterol 97(3):52834.
    Direct Link:
  • Lee KS, Lee BS, Semnani S, Avanesian A, Um CY, Jeon HJ, Seong KM, Yu K, Min KJ, Jafari M. 2010a. Curcumin extends life span, improves health span, and modulates the expression of age-associated aging genes in Drosophila melanogaster. Rejuv Res 13(5):56170.
  • Lee KH, Yeh MH, Kao ST, Hung CM, Liu CJ, Huang YY, Yeh CC. 2010b. The inhibitory effect of hesperidin on tumor cell invasiveness occurs via suppression of activator protein 1 and nuclear factor-kappaB in human hepatocellular carcinoma cells. Toxicology Lett 194(1):429.
  • Leu TH, Maa MC. 2002. The molecular mechanisms for the antitumorigenic effect of curcumin. Curr Med Chem-Anti-Cancer Agent 2(3):35770.
  • Leuschner U. 2003. Primary biliary cirrhosis-presentation and diagnosis. Clin Liver Dis 7:74158.
  • Li M, Zhang Z, Hill DL, Wang H, Zhang R. 2007. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 67(5):198896.
  • Liang J, Slingerland JM. 2003. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2(4):33642.
  • Liaw YF, Chu CM. 2009. Hepatitis B virus infection. Lancet 373(9663):58292.
  • Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. 2001. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21(21):83707.
  • Limtrakul P, Lipigorngoson S, Namwong O, Apisariyakul A, Dunn FW. 1997. Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. Cancer Lett 116(2):197203.
  • Lin JK. 2007. Molecular targets of curcumin. In: Aggarwal, Bharat B.; Surh, Young-Joon; Shishodia, S. editor., The molecular targets and therapeutic uses of curcumin in health and disease. New York NY, USA: Springer. p. 22743.
  • Lin LI, Ke YF, Ko YC, Lin JK. 1998. Curcumin inhibits SK-Hep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion. Oncology 55(4):34953.
  • Lin JK, Lin-Shiau SY. 2009. Turmeric (curcumin). In: Bharat B. Aggarwal, Ajaikumar B. Kunnumakkarap, editors. Molecular targets and therapeutic uses of spices: modern uses for ancient medicine. Singapore: World Scientific. p.403.
  • Lindor K. 2007. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 357(15):15249.
  • Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F. 2009. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50(3):80814.
  • Liu ZX, Kaplowitz N. 2002. Immune-mediated drug-induced liver disease. Clin Liver Dis 6(3):75574.
  • Liu P, Kimmoun E, Legrand A, Sauvanet A, Degott C, Lardeux B, Bernuau D. 2002. Activation of NF-kappaB, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J Hepatol 37(1):6371.
  • Liu Q, Loo WT, Sze SCW, Tong Y. 2009. Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFκB, cyclinD and MMP-1 transcription. Phytomedicine 16(10):91622.
  • Liu Q, Yuan B, Lo KA, Patterson HC, Sun Y, Lodish HF. 2012a. Adiponectin regulates expression of hepatic genes critical for glucose and lipid metabolism. Proc Natl Acad Sci 109(36):1456873.
  • Liu K, Chen HL, Huang H, Jing H, Dong GH, Wu HW, You QS. 2012b. Curcumin attenuates cardiopulmonary bypass-induced lung oxidative damage in rats. J Cardiovasc Pharmacol Ther 17(4):395402.
  • Lo HW, Cao X, Zhu H, Ali-Osman F. 2010. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol Cancer Res 8(2):23245.
  • Lucey MR, Mathurin P, Morgan TR.2009. Alcoholic hepatitis. N Engl J Med 360(26):275869.
  • MacFarlane M, Merrison W, Bratton SB, Cohen GM. 2002. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem 277(39):366116.
  • Marczylo TH, Steward WP, Gescher AJ. 2009. Rapid analysis of curcumin and curcumin metabolites in rat biomatrices using a novel ultraperformance liquid chromatography (UPLC) method. J Agric Food Chem 57(3):797803.
  • Martin RC, Aiyer HS, Malik D, Li Y. 2012. Effect on pro-inflammatory and antioxidant genes and bioavailable distribution of whole turmeric vs curcumin: similar root but different effects. Food Chem Toxicol 50(2):22731.
  • Mathew A, Peiffer LP, Rhoades K, McGarrity T. 2006. Sustained viral response to pegylated interferon α-2b and ribavirin in chronic hepatitis C refractory to prior treatment. Dig Dis Sci 51(11):195661.
  • Mendes F, Lindor KD. 2010. Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol 7(11):6119.
  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC. 2002. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 99(11):407986.
  • Miura H, Miyachi Y. 2009. IgG4-related retroperitoneal fibrosis and sclerosing cholangitis independent of autoimmune pancreatitis. A recurrent case after a 5-year history of spontaneous remission. JOP 10:4327.
  • Mohamad N, Gutiérrez A, Núñez M, Cocca C, Martín G, Cricco G, Medina V, Rivera E, Bergoc R. 2005. Mitochondrial apoptotic pathways. Biocell 29(2):14961.
  • Mohanty C, Sahoo SK. 2010. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 31(25):6597611.
  • Mokdad AH, Marks JS, Stroup DF, Gerberding JL. 2004. Actual causes of death in the United States, 2000. JAMA 291(10):123845.
  • Morisco F, Vitaglione P, Amoruso D, Russo B, Fogliano V, Caporaso N. 2008. Foods and liver health. Mol Asp Med 29(1):14450.
  • Muir AJ, Bornstein JD, Killenberg PG. 2004. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350(22):226571.
  • Mythri BR, Srinivas M, Bharath M. 2012. Curcumin: a potential neuroprotective agent in Parkinsons disease. Curr Pharmaceut Des 18(1):919.
  • Nabavi SF, Eslami S, Moghaddam AH, Nabavi SM. 2011a. Protective effects of curcumin against fluoride-induced oxidative stress in the rat brain. Neurophysiology 43(4):28791.
  • Nabavi SF, Moghaddam AH, Eslami S, Nabavi SM. 2012a. Protective effects of curcumin against sodium fluoride-induced toxicity in rat kidneys. Biol Trace Element Res 145(3):36974.
  • Nabavi SF, Nabavi SM, Abolhasani F, Moghaddam AH, Eslami S. 2012b. Cytoprotective effects of curcumin on sodium fluoride-induced intoxication in rat erythrocytes. B Environ Contam Toxicol 88:48690.
  • Nabavi SF, Nabavi SM, Ebrahimzadeh MA, Eslami S, Jafari N, Moghaddam HA. 2011b. The protective effect of curcumin against sodium fluoride-induced oxidative stress in rat heart. ArchBiol Sci 63(3):5639.
  • Nabavi SM, Nabavi SF, Eslami S, Moghaddam AH. 2012c. In vivo protective effects of quercetin against sodium fluoride-induced oxidative stress in the hepatic tissue. Food Chem 132(2):9315.
  • Nakagawa H, Maeda S, Hikiba Y, Ohmae T, Shibata W, Yanai A, Sakamoto K, Ogura K, Noguchi T, Karin M, Ichijo H, Omata M. 2008. Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology 135(4):131121.
  • Nanji AA, Jokelainen K, Rahemtulla A, Miao L, Fogt F, Matsumoto H, Tahan SR, Su GL. 1999. Activation of nuclear factor kappa B and cytokine imbalance in experimental alcoholic liver disease in the rat. Hepatology 30(4):93443.
  • Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, Dannenberg AJ. 2003. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-κB-dependent genes. Am J Physiol-Gastrointest Liver Physiol 284(2):G3217.
  • Natarajan C, Bright JJ. 2002. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 168(12):650613.
  • Nautiyal J, Banerjee S, Kanwar SS, Yu Y, Patel BB, Sarkar FH, Majumdar AP. 2010. Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. Intl J Cancer 128(4):95161.
  • Navarro VJ, Senior JR. 2006. Drug-related hepatotoxicity. N Engl J Med 354(7):7319.
  • Naveau S, Dobrin AS, Balian A, Njiké-Nakseu M, Nohra P, Asnacios A, Prévot S, Perlemuter G. 2013. Body fat distribution and risk factors for Fibrosis in patients with alcoholic liver disease. Alcohol Clin Exp Res 37:3328.
  • Negi AS, Kumar JK, Luqman S, Shanker K, Gupta MM, Khanuja SPS. 2008. Recent advances in plant hepatoprotectives: a chemical and biological profile of some important leads. Med Res Rev 28(5):74672.
  • Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H. 2002. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21(13):20008.
  • Ng APP, Chng WJ, Khan M. 2011. Curcumin sensitizes acute promyelocytic leukemia cells to unfolded protein response–induced apoptosis by blocking the loss of misfolded N-CoR protein. Mol Cancer Res 9(7):87888.
  • Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D'Alessandro N. 2005. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 224(1):5365.
  • Nurfina AN, Reksohadiprodjo MS, Timmerman H, Jenie UA, Sugiyanto D, van der Goot H. 1997. Synthesis of some symmetrical curcumin derivatives and their antiinflammatory activity. Eur J Med Chem 32:3218.
  • Oconnell MA, Rushworth SA. 2008. Curcumin: potential for hepatic fibrosis therapy? Br J Pharmacol 153(3):4035.
  • Oetari S, Sudibyo M, Commandeur JN, Samhoedi R, Vermeulen NP. 1996. Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver. Biochem Pharmacol 51(1):3945.
  • Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, Hardies J, Cusi K. 2012. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 35(4):8738.
  • Pan MH, Lin-Shiau SY, Lin JK.2000. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol 60:166576.
  • Pan Y, Zhu G, Wang Y, Cai L, Cai Y, Hu J, Li Y, Yan Y, Wang Z, Li X, Wei T, Liang G. 2013. Attenuation of high-glucose-induced inflammatory response by a novel curcumin derivative B06 contributes to its protection from diabetic pathogenic changes in rat kidney and heart. J Nutr Biochem 24(1):14655.
  • Papa S, Bubici C, Zazzeroni F, Pham CG, Kuntzen C, Knabb JR, Dean K, Franzoso G. 2006. The NF-κB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ 13(5):71229.
  • Pari L, Murugan P. 2004. Protective role of tetrahydrocurcumin against erythromycin estolate-induced hepatotoxicity. Pharmacol Res 49(5):4816.
  • Paula H, Asrani SK, Boetticher NC, Pedersen R, Shah VH, Kim WR. 2010. Alcoholic liver disease-related mortality in the United States: 1980–2003. Am J Gastroenterol 105(8):17827.
  • Peng BG, He Q, Li JP, Zhou F. 2009. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg 198(3):3138.
  • Pessayre D, Mansouri A, Berson A, Fromenty B. 2010. Mitochondrial involvement in drug-induced liver injury. Adv Drug React 2010:31165.
  • Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45(4):52938.
  • Pham CG, Bubici C, Zazzeroni F, Knabb JR, Papa S, Kuntzen C, Franzoso G. 2007. Upregulation of Twist-1 by NF-κB blocks cytotoxicity induced by chemotherapeutic drugs. Mol Cell Biol 27(11):392035.
  • Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K, Jayawardena S, De Smaele E, Cong R, Beaumont C, Torti FM, Torti SV, Franzoso G. 2004. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 119(4):52942.
  • Poynard T, Bedossa P, Opolon P. 1997. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349(9055):82532.
  • Pratsinis H, Giannouli CC, Zervolea I, Psarras S, Stathakos D, Kletsas D. 2004. Differential proliferative response of fetal and adult human skin fibroblasts to transforming growth factor-β. Wound Repair Regen 12(3):37483.
  • Priyadarsini KI. 2009. Photophysics, photochemistry and photobiology of curcumin: studies from organic solutions, bio-mimetics and living cells. J Photochem Photobiol C Photochem Rev 10(2):8195.
  • Prusty BK, Das BC. 2004. Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Intl J Cancer 113(6):95160.
  • Pullakhandam R, Srinivas PNBS, Nair MK, Reddy GB. 2009. Binding and stabilization of transthyretin by curcumin. Arch Biochem Biophys 485(2):1159.
  • Puri P, Sanyal AJ. 2012. Nonalcoholic fatty liver disease: definitions, risk factors, and workup. Clin Liver Dis 1(4):98102.
  • Punithavathi D, Venkatesan N, Babu M. 2009. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. Br J Pharmacol 131(2):16972.
  • Quasdorff M, Hösel M, Odenthal M, Zedler U, Bohne F, Gripon P, Dienes HP, Drebber U, Stippel D, Goeser T, Protzer U. 2008. A concerted action of HNF4α and HNF1α links hepatitis B virus replication to hepatocyte differentiation. Cell Microbiol 10(7):147890.
  • Quasdorff M, Protzer U. 2010. Control of hepatitis B virus at the level of transcription. J Viral Hepat 17(8):52736.
  • Rajasekaran SA. 2011. Therapeutic potential of curcumin in gastrointestinal diseases. World J Gastrointest Pathophysiol 2(1):114.
  • Ramirez-Tortosa MC, Ramirez-Tortosa CL, Mesa MD, Granados S, Gil Á, Quiles JL. 2009. Curcumin ameliorates rabbits steatohepatitis via respiratory chain, oxidative stress, and TNF-α. Free Rad Biol Med 47(7):92431.
  • Rasyid A, Lelo A. 1999.The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther 13(2):2459.
  • Rechtman MM, Har-Noy O, Bar-Yishay I, Fishman S, Adamovich Y, Shaul Y, Halpern Z, Shlomai A. 2010. Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1α. FEBS Lett 584(11):248590.
  • Reyes-Gordillo K, Segovia J, Shibayama M, Tsutsumi V, Vergara P, Moreno MG, Muriel P. 2008. Curcumin prevents and reverses cirrhosis induced by bile duct obstruction or CCl4 in rats: role of TGF-β modulation and oxidative stress. Fundam Clin Pharmacol 22(4):41727.
  • Rivera-Espinoza Y, Muriel P. 2009. Pharmacological actions of curcumin in liver diseases or damage. Liver Intl 29(10):145766.
  • Rousseau S, Houle F, Landry J, Huot J. 1997. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15(18):216977.
  • Romero-Hernández MA, Eguía-Aguilar P, Perézpeña-Diazconti M, Rodríguez-Leviz A, Sadowinski-Pine S, Velasco-Rodríguez LA, Cáceres CJ, Arenas-Huertero F. 2013.Toxic effects induced by curcumin in human astrocytoma cell lines. Toxicol Mech Methods. Available from http://informahealthcare.com/doi/pdf/10.3109/15376516.2013.826768.
  • Saich R, Chapman R. 2008. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol 14(3):3317.
  • Salunga TL, Cui ZG, Shimoda S, Zheng HC, Nomoto K, Kondo T, Takano Y, Selmi C, Alpini G, Gershwin ME, Tsuneyama K. 2007. Oxidative stress-induced apoptosis of bile duct cells in primary biliary cirrhosis. J Autoimmun 29(2):7886.
  • Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, Limtrakul P, Badmaev V, Aggarwal BB. 2007. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 28(8):176573.
  • Sargent S. 2008. Diagnosing and treating a patient with primary biliary cirrhosis. Br J Nurs 17(9):56670.
  • Scapagnini G, Sonya V, Nader AG, Calogero C, Zella D, Fabio G. 2011. Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol 44(2):192201.
  • Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR, Schmid KW, Baba HA. 2008. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48(1):8390.
  • Semela D, Dufour JF. 2004. Angiogenesis and hepatocellular carcinoma. J Hepatol 41(5):86480.
  • Sethi G, Sung B, Aggarwal BB. 2009. In: Ramawat K. G., editor. The role of curcumin in modern medicine, Herbal drugs: ethnomedicine to modern medicine. Berlin Heidelberg: Springer. p. 97113.
  • Shah BH, Nawaz Z, Pertani SA, Roomi A, Mahmood H, Saeed SA, Gilani AH. 1999. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor-and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca 2+ signaling. Biochem Pharmacol 58(7):116772.
  • Sharma AV, Ganguly K, Paul S, Maulik N, Swarnakar S. 2012. Curcumin heals indomethacin-induced gastric ulceration by stimulation of angiogenesis and restitution of collagen fibers via VEGF and MMP-2 mediated signaling. Antioxid Red Signal 16(4):35162.
  • Shehzad A, Lee YS. 2010. Curcumin: multiple molecular targets mediate multiple pharmacological actions: a review. Drug Future 35:1139.
  • Shehzad A, Wahid F, Lee YS. 2010. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharmazie 343(9):48999.
  • Shen H, Huang GJ, Gong YW. 2003. Effect of transforming growth factor beta and bone morphogenetic proteins on rat hepatic stellate cell proliferation and trans-differentiation. World J Gastroenterol 9(4):7847.
  • Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, Lau WY, Li JQ. 2007. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg 245(1):3643.
  • Shin SK, Ha TY, McGregor RA, Choi MS. 2011. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res 55:182940.
  • Shishodia S, Sethi G, Aggarwal BB. 2006. Curcumin: getting back to the roots. Annu New York Acad Sci 1056(1):20617.
  • Shlomai A, Paran N, Shaul Y. 2006. PGC-1α controls hepatitis B virus through nutritional signals. Proc Natl Acad Sci 103(43):160038.
  • Sidhu GS, Singh AK, Thaloor D, Banaudha KK, Patnaik GK, Srimal RC, Maheshwari RK. 2002. Enhancement of wound healing by curcumin in animals. Wound Repair Regener 6(2):16777.
  • Simard EP, Ward EM, Siegel R, Jemal A.2012. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA: A Cancer J Clin 62:11828.
  • Singal AK, Stanca CM, Clark V, Dixon L, Levy C, Odin JA, Fiel MI, Friedman SL, Bach N. 2011. Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature. Hepatol Intl 5(3):80813.
  • Singh U, Barik A, Singh BG, Priyadarsini KI. 2011. Reactions of reactive oxygen species (ROS) with curcumin analogues: structure-activity relationship. Free Rad Res 45(3):31725.
  • Somparn P, Phisalaphong C, Nakornchai S, Unchern S, Morales NP. 2007. Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol Pharm Bull 30(1):7478.
  • St-Germain ME, Gagnon V, Parent S, Asselin E. 2004. Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-κB/IκB pathway. Mol Cancer 3(1):7.
  • Stokkeland K, Ebrahim F, Ekbom A. 2010. Increased risk of esophageal varices, liver cancer, and death in patients with alcoholic liver disease. Alcohol Clin Exp Res 34(11):19939.
  • Subramaniam D, Ponnurangam S, Ramamoorthy P, Standing D, Battafarano RJ, Anant S, Sharma P. 2012. Curcumin induces cell death in esophageal cancer cells through modulating notch signaling. PLoS One 7(2):e30590.
  • Sun B, Karin M. 2008. NF-κB signaling, liver disease and hepatoprotective agents. Oncogene 27(48):622844.
  • Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, Qiu SJ, Shen YF. 2006. Postoperative interferon α treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 132(7):45865.
  • Suresh Babu P, Srinivasan K. 1995. Influence of dietary curcumin and cholesterol on the progression of experimentally induced diabetes in albino rat. Mol Cell Biochem 152(1):1321.
  • Suter PM, Tremblay A. 2005. Is alcohol consumption a risk factor for weight gain and obesity? Crit Rev Clin Lab Sci 42(3):197227.
  • Tabibian JH, Lindor KD. 2013. Primary sclerosing cholangitis: a review and update on therapeutic developments. Exp Rev Gastroenterol Hepatol 7(2):10314.
  • Tacke F, Luedde T, Trautwein C. 2009. Inflammatory pathways in liver homeostasis and liver injury. Clin RevAllergy Immunol 36(1):412.
  • Talwalkar JA, Lindor KD. 2003. Primary biliary cirrhosis. Lancet 362(9377):5361.
  • Tanaka A, Borchers AT, Ishibashi H, Ansari AA, Keen CL, Gershwin ME. 2001. Genetic and familial considerations of primary biliary cirrhosis. Am J Gastroenterol 96(1):815.
    Direct Link:
  • Tanaka S, Miyanishi K, Kobune M, Kawano Y, Hoki T, Kubo T, Hayashi T, Sato T, Sato Y, Takimoto R, Kato J. 2013. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J Gastroenterol. Doi:10.1007/s00535-012-0739-0.
  • Teiten MH, Eifes S, Dicato M, Diederich M. 2010. Curcumin—the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. Toxins 2(1):12862.
  • Thangapazham RL, Sharma A, Maheshwari RK. 2007. Beneficial role of curcumin in skin diseases. In: Aggarwal, Bharat B.; Surh, Young-Joon; Shishodia, S., editors. The molecular targets and therapeutic uses of curcumin in health and disease. New York, NY, USA: Springer. p 34357.
  • Thapliyal R, Maru GB. 2001. Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem Toxicol 39(6):5417.
  • Tiniakos DG, Vos MB, Brunt EM. 2010. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 5:14571.
  • Ueki M, Ueno M, Morishita J, Maekawa N. 2012. Curcumin ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice. J Biosci Bioeng 115(5):54751.
  • Vara D, Salazar M, Olea-Herrero N, Guzmán M, Velasco G, Díaz-Laviada I. 2011. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ 18(7):1099111.
  • Verhoef C, Valkema R, De Man RA, Krenning EP, Yzermans JNM. 2002. Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography. Liver 22(1):516.
  • Vizzutti F, Provenzano A, Galastri S, Milani S, Delogu W, Novo E, Caligiuri A, Zamara E, Arena U, Laffi G, Parola M, Pinzani M, Marra F. 2009. Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab Invest 90(1):10415.
  • Vogel A, Manns MP. 2012. Mimics of autoimmune hepatitis: drug-induced and immune mediated liver disease. Autoimmun Hepat 2012:93113.
  • Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM. 2000. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 10(21):135966.
  • Wada T, Penninger JM. 2004. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23(16):283849.
  • Wands J. 2007. Hepatocellular carcinoma and sex. N Engl J Med 357(19):19746.
  • Wang WZ, Li L, Liu MY, Jin XB, Mao JW, Pu QH, Meng MJ, Chen XG, Zhu JY. 2013. Curcumin induces FasL-related apoptosis through p38 activation in human hepatocellular carcinoma Huh7 cells. Life Sci 92(6–7):3528.
  • Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS. 1998. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281(5383):16803.
  • Wang NP, Wang ZF, Tootle S, Philip T, Zhao ZQ. 2012. Curcumin promotes cardiac repair and ameliorates cardiac dysfunction following myocardial infarction. Br J Pharmacol 167:155062.
  • Warrington R. 2012. Drug allergy: causes and desensitization. Hum Vaccine Immunother 8(10):151324.
  • Watson JL, Greenshields A, Hill R, Hilchie A, Lee PW, Giacomantonio CA, Hoskin DW. 2010. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. Mol Carcinog 49(1):1324.
  • Wilken R, Veena MS, Wang MB, Srivatsan ES. 2011. Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 10(12):119.
  • Woodhead JL, Howell BA, Yang Y, Harrill AH, Clewell 3rd HJ, Andersen ME, Siler SQ, Watkins PB. 2012. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther 342(2):52940.
  • Wu Z, Han M, Chen T, Yan W, Ning Q. 2010. Acute liver failure: mechanisms of immune-mediated liver injury. Liver Intl 30(6):78294.
  • Wu JY, Lin CY, Lin TW, Ken CF, Wen YD. 2007. Curcumin affects development of zebrafish embryo. Biol Pharm Bull 30(7):13369.
  • Xia Y, Jin L, Zhang B, Xue H, Li Q, Xu Y. 2007. The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life Sci 80(23):21619.
  • Yadav A, Lomash V, Samim M, Flora SJ. 2012. Curcumin encapsulated in chitosan nanoparticles: a novel strategy for the treatment of arsenic toxicity. Chem-Biol Interact 199(1):4961.
  • Yan G, Graham K, Lanza-Jacoby S. 2012. Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells. Mol Carcinog 52(5):40411.
  • Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM. 2005. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280(7):5892901.
  • Yang Y, Zhu J, Gou H, Cao D, Jiang M, Hou M. 2011. Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC). Med Oncol 28(3):796803.
  • Yao QY, Xu BL, Wang JY, Liu HC, Zhang SC, Tu CT. 2012. Inhibition by curcumin of multiple sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats. BMC Complment Altern Med 12(1):156.
  • Yoysungnoen P, Wirachwong P, Bhattarakosol P, Niimi H, Patumraj S. 2006. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin Hemorheol Microcirc 34(1):10915.
  • Yu YD, Kim KH, Lee SG, Choi SY, Kim YC, Byun KS, Cha IH, Park KY, Cho CH, Choi DH. 2011. Hepatic differentiation from human embryonic stem cells using stromal cells. J Surg Res 170:e25361.
  • Yu G, Liu L, Zhang P, Li Y. 2012. Protective effect of curcumin on chronic cerebral ischemia by altering expression of α-synuclein in 2VO model. Mol Neurodegener 7:S33.
  • Zhang W, Liu HT.2002. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12(1):918.
  • Zhao D, Chen S, Cai J, Guo Y, Song Z, Che J, Liu C, Wu C, Ding M, Deng H. 2009. Derivation and characterization of hepatic progenitor cells from human embryonic stem cells. PloS One 4(7):e6468.
  • Zhao J, Jin J, Zhang X, Shi M, Dai J, Wu M, Wang R, Guo Y. 2006. Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivo. Cancer Gene Ther 13:4207.
  • Zheng S, Chen A. 2006. Curcumin suppresses the expression of extracellular matrix genes in activated hepatic stellate cells by inhibiting gene expression of connective tissue growth factor. Am J Physiol Gastrointest Liver Physiol 290(5):G88393.
  • Zoulim F. 2004a. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir Chem Chemother 15(6):299305.
  • Zoulim F. 2004b. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antivir Res 64(1):115.